An interventional study of Transcervical resection of septum in Infertility and Miscarriage, sponsored by The Third Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by The Third Xiangya Hospital of Central South University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Infertility with a site in China — 38 open to participants now, 41 under way, 5 of them phase 3. Infertility · China.
Among the 139 studies in Infertility with a site in China, this one is the 34th largest by planned enrollment of the 107 interventional ones that give a count, is one of 14 that started in 2025, is one of 65 with no phase, reaches primary completion later than 33 of the 40 other live ones, and was the 120th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →38 of the 139 studies in Infertility with a site in China are open now. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 20–40 · Women only
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 36–39 · Women only
Li Li · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Sites in China
Ages 20–40 · Women only
Tang-Du Hospital · Sites in China
Ages 20–45 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 15 · Phase 4 14
First in 2003; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 418 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 248 across the 107 interventional studies, 550 across the 32 observational. Of the 56 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 139 have an industry lead sponsor. The 10 most frequent:
The Third Xiangya Hospital of Central South University is the lead sponsor of 99 studies on the registry; 52 are open to participants now.
The Third Xiangya Hospital of Central South University has 3 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
12 of the studies in Infertility with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT07696351Li-jun DingUltra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis | 2026-12-31 |
| NCT07050537The First Affiliated Hospital with Nanjing Medical UniversityA Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology | 2027-03-31 |
| NCT07533630Reproductive & Genetic Hospital of CITIC-XiangyaProspective International Multi-center Clinical Trial of PGT-A Upgrade | 2027-06 |
Add all 12 to your calendar (.ics) → With an account.
Among the 139 studies in Infertility with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to compare the effects of transcervical resection of septa (TCRS) and expectant management on the natural pregnancy outcomes of patients with septate uterus without recurrent abortion, also covering the treatment of other infertility factors in infertile patients who aim at natural conception. The research attempts to answer whether TCRS can improve the live birth rate, pregnancy rate and pregnancy outcomes for septate uterus patients planning natural pregnancy, so as to provide evidence-based medical evidence for the selection of clinical treatment methods for such patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Undergoing Transcervical resection of septum
Procedure: Transcervical resection of septum
Routine preconception counseling and observation without hysteroscopic septectomy
Transcervical resection of septum (TCRS) is divided into two categories: one is plasma hysteroscopic electrosurgical resection (actually TCIS), which uniformly uses a 7mm external diameter hysteroscopic electrosurgical resectoscope to reduce the difficulty of cervical dilation; the other is micro (5 or 7Fr) hysteroscopic cold knife incision, equipped with a 5Fr bipolar electrocoagulation stick for electrocoagulation and hemostasis.
live birth rate
Follow-up was conducted for 12 months after the surgery or treatment course to record the IVF/ICSI reproductive outcomes within 12 months after the initiation of embryo transfer into the cycle.
Time frame: within 12 months after initiating embryo transfer
Adverse outcome rate
Pregnancy rate and cumulative pregnancy rate, miscarriage rate and cumulative miscarriage rate, preterm birth rate.
Time frame: within 12 months after initiating embryo transfer in both groups
PDFs hosted by the registry, ClinicalTrials.gov.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.
Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 42 months is above that.
Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Third Xiangya Hospital of Central South University